A unique and universal antibacterial coating for prevention of hospital acquired...
A unique and universal antibacterial coating for prevention of hospital acquired infections associated with the use of medical devices
The aim of the current project is to develop a strong business plan that includes market analysis and clinical validation strategies to commercialise CytaCoat. 1 in 18 patients in a European hospital acquire Healthcare-Associated...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MAT2015-67648-R
NANORECUBRIMIENTOS HIBRIDOS CON MEJORADA EFICIENCIA ANTIMICR...
121K€
Cerrado
SPARTHACUS
Innovative multifunctional and smart coatings to prevent med...
3M€
Cerrado
COATIM
Development of antibiofilm coatings for implants
4M€
Cerrado
NOVO
Novel approaches for prevention and degeneration of pathogen...
4M€
Cerrado
PID2021-127847OB-I00
DISEÑO DE DISPOSITIVOS MEDICOS Y DESARROLLO DE RECUBRIMIENTO...
198K€
Cerrado
PHOTO-IASIS
Nanoengineered coatings for visible light photocatalytic dis...
192K€
Cerrado
Información proyecto CYTAMED
Duración del proyecto: 6 meses
Fecha Inicio: 2018-07-23
Fecha Fin: 2019-01-31
Líder del proyecto
CYTACOAT AKTIEBOLAG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of the current project is to develop a strong business plan that includes market analysis and clinical validation strategies to commercialise CytaCoat. 1 in 18 patients in a European hospital acquire Healthcare-Associated Infections (HAIs) mainly as a result of colonisation and formation of microbial biofilms on the surface of medical devices that are in lengthy contact with patients. At present, antimicrobial substances and silver agent coating are used as preventative measures, while antibiotics are used for treatment following HAIs. These strategies either contribute to antimicrobial resistance or potentially dangerous due to the release of harmful silver substances in the body. To overcome this, CytaCoat has developed a unique and stable antimicrobial coating that uses non-toxic, biocompatible organic compounds that strongly bind to the surface of the device through covalent bonding. This impedes microbial colonization and reduces the likelihood of antimicrobial resistance to the coating. These features distinguish CytaCoat from all competing products on the market. The first application for the coating are neonatal nasal prongs for non-invasive ventilation support, however the coating can be applied to all invasive and non-invasive medical devices. The research performed to date strongly supports CytaCoat’s ability to hinder microbial colonisation. The coating is easily applied to all devices using a defined protocol developed by the company. This project will help facilitate the road towards commercialisation.